Orchid Pharma Limited — Others, 12-08-2025: Monitoring Agency Report

Orchid Pharma's monitoring report on its Rs 400 Cr QIP proceeds shows no deviation from stated objectives. Of the total, Rs 269.69 Cr has been utilized, with Rs 124.85 Cr remaining in Fixed Deposits. Key projects face delays. The Alathur API facility's progress is hindered because its primary product source, the Jammu manufacturing facility, is experiencing land acquisition delays. While most land for Jammu is secured and initial construction has begun, securing agreements from various farmers and obtaining necessary land use approvals caused setbacks. This update provides clarity on project timelines and fund deployment.